Artivion (NYSE:AORT) Insider John Davis Sells 3,773 Shares of Stock

Artivion, Inc. (NYSE:AORT) insider John Davis sold 3,773 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $37.59, for a total transaction of $141,827.07. Following the sale, the insider owned 190,943 shares in the company, valued at approximately $7,177,547.37. The trade was a 1.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Artivion Price Performance

Shares of AORT traded up $0.98 during mid-day trading on Thursday, reaching $36.76. The stock had a trading volume of 30,985 shares, compared to its average volume of 389,761. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of 183.81 and a beta of 1.59. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25. The business has a fifty day moving average of $42.27 and a 200 day moving average of $43.08. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The company’s quarterly revenue was up 19.2% compared to the same quarter last year. Equities analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Canaccord Genuity Group lowered their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Finally, Citizens Jmp increased their price objective on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $48.97.

Artivion News Roundup

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Company beat recent quarterly estimates — revenue grew ~19% year‑over‑year and EPS topped consensus in the Feb. 12 report, supporting the bullish case for revenue momentum and margin recovery. Earnings & Company Page
• Positive Sentiment: Short interest fell materially in February (down ~15.4% month‑over‑month to ~1.39M shares, ~3.2% of float), lowering near‑term downside pressure from short covering and making upward moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Large institutional moves show conviction: several funds (Summit Partners, Invesco, Goldman, Two Sigma) increased or initiated sizeable positions in recent quarters, suggesting longer‑term buy interest from professional investors. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed but skewed positive: consensus is a “Moderate Buy” with a ~$49 average target, though several shops have trimmed price targets or moved to hold — signaling diverging views on near‑term upside. Analyst Notes
• Negative Sentiment: Substantial insider selling across senior management over Feb. 23–24 (CEO James P. Mackin sold multiple blocks totaling tens of thousands of shares, plus sales by the EVP, SVPs and CAO). While filings indicate open‑market sales (liquidity/rebalancing), the size and breadth of the dispositions can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Institutional Trading of Artivion

Several hedge funds have recently made changes to their positions in AORT. Invesco Ltd. lifted its holdings in shares of Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after acquiring an additional 748,119 shares during the last quarter. XTX Topco Ltd purchased a new stake in Artivion during the fourth quarter valued at approximately $746,000. Susquehanna Portfolio Strategies LLC lifted its stake in shares of Artivion by 21.5% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company’s stock valued at $1,849,000 after purchasing an additional 7,186 shares during the last quarter. Occudo Quantitative Strategies LP purchased a new position in shares of Artivion in the 4th quarter worth approximately $248,000. Finally, Millennium Management LLC increased its position in shares of Artivion by 1.0% during the 4th quarter. Millennium Management LLC now owns 91,816 shares of the company’s stock valued at $4,188,000 after purchasing an additional 893 shares during the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.